Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our Wave 2 products, DARZALEX/FASPRO and Phesgo, launched in 2020, have driven the impressive royalty revenues and growth illustrated on this chart and have many years of impressive growth ahead for them |
| We continue to have strong and expanding interest by existing and new partners |
| And so, it's a very good thing for us to demonstrate our effectiveness in managing and delivering auto-injectors, but also the high reliability of our device |
| For 2023, we delivered a 26% year-over-year increase in total revenue to $829 million and reached a record $448 million in royalty revenue, which represents a 24% year-over-year increase |
| Strong operational performance drove another year of double-digit earnings growth, with adjusted EBITDA increasing 19% to $426 million and non-GAAP diluted earnings per share growth of 25% to $2.77 for the full year 2023 |
| We also deployed $400 million to shareholders through share repurchases, reflecting strong cash flow and disciplined capital allocation priorities |
| Our achievements and our partner progress in 2023 contributed to the strong performance and paved the path for our strong long-term outlook |
| And so, it is a great fit from the point of view of adding to our revenue, diversifying our revenue, but also contributing meaningful EBITDA, even on our very large revenue base that we project in 2028 |
| We project the availability of ocrelizumab subcutaneous with ENHANZE can create increased growth in two key ways: firstly, by allowing current multiple sclerosis centers to increase the number of patients treated as a result of improved throughput based on shorter time needed for each patient occupying an infusion chair; and secondly, by expanding the number of treatment centers by enabling multiple sclerosis centers that do not have IV infrastructure today to start administering ocrelizumab subcutaneously |
| We also had multiple positive Phase 3 data readouts supporting regulatory submissions for approval of the enhanced subcutaneous formulations |
| I think the team has done over 20 human factors studies very successfully also, to support regulatory filings |
| VYVGART Hytrulo Phase 3 data in CIDP was the first positive Phase 3 readout and upon approval, creates an expanded commercial opportunity in the condition where there is high unmet need today |
| And so, the biggest thing is just helping them understand this is built on an incredible background platform with great experience from our engineers, track record of success with regulators |
| We were also very excited with the positive data announcements from two additional Wave 3 products, Roche's Ocrelizumab subcutaneous ENHANZE and Bristol Myers Squibb's Nivolumab subcutaneous within ENHANZE, supporting global regulatory submissions and potential launch in 2024 for Ocrelizumab subcu and in 2025 for Nivolumab subcu |
| And of course, that's another of the advantages of our Antares platform, is that it is tested to the highest levels of reliability for several of our products like the EpiPen |
| We are delighted that Johnson & Johnson recently announced strong progress with the Phase 3 study that they project will support submission of regulatory filings in 2024 for subcutaneous amivantamab with ENHANZE |
| With subcutaneous penetration in excess of 90% in the U.S., total brand growth has become the key driver for understanding subcutaneous performance for this product |
| Also in 2023, we reached an important milestone for our new high-volume auto-injector as we successfully demonstrated the feasibility of administering a subcutaneous injection of 10 milliliters of representative biologic immune globulin 10% with enhanced in approximately 30 seconds using our high volume auto-injector |
| So that long track record of success and the track record of approvals of drug device combinations is pretty much unmatched, we believe, in the industry |
| and outside the U.S., which is why I think we're seeing such nice growth of Phesgo in all regions of the world |
| With our strong track record of success and progress, as we look ahead, we have high confidence in the visibility of our revenue and we were delighted to recently share our 2024 guidance and our five-year financial outlook for the company |
| For 2024, we're delighted to project continued strong growth of revenue with a guidance range of $915 million to $985 million, representing 10% to 19% year-over-year growth |
| And so, I think those are two examples that say, a reduction in time from an hour-long IV to a five-minute subcu is very attractive in the market |
| As I mentioned on the call, already 40% conversion, very close to that in the 46 launch countries, and certainly showing strong adoption, with 40% of sales also coming from the United States now |
| Opdivo IV sales were $9 billion in 2023, increasing 9% year-over-year, showing continued strong growth |
| And impressively, we project adjusted EBITDA will grow faster than revenue in every year of the five-year outlook to an impressive $1 billion in 2028 with a five-year CAGR of 23% |
| But again, a very nice global conversion |
| Given in just five minutes, nivolumab subcutaneous has the potential to be practice-changing and to improve the patient's treatment experience |
| We're very pleased to report our strong financial and operating results in the fourth quarter and for the full year of 2023 |
| This strong growth was driven by share gains in all regions and continued growth in the first line setting |
| Statement |
|---|
| And I think in the world where not just outside the U.S., but in the U.S., we're also seeing major infusion suite capacity constraints |
| And so I would say just think about it as a little bit of a slow uptake for the first six months and then no real barriers |
| Because what we understand is that there have been some, particularly on-body injectors that have been tried over the last several years that have not delivered with the reliability that was required |
| I would also refer you to our SEC filings for a full list of risks and uncertainties |
| Just 20% of patients get remission on the current standard of care treatment and 50% of patients report that they remain dissatisfied with the current burden of symptoms |
| in the future |
Please consider a small donation if you think this website provides you with relevant information